THOMAS A BUCHHOLZ to Prognosis
This is a "connection" page, showing publications THOMAS A BUCHHOLZ has written about Prognosis.
Connection Strength
0.797
-
Influence of neoadjuvant chemotherapy on radiotherapy for breast cancer. Ann Surg Oncol. 2015 May; 22(5):1434-40.
Score: 0.037
-
Optimising radiation treatment decisions for patients who receive neoadjuvant chemotherapy and mastectomy. Lancet Oncol. 2012 Jun; 13(6):e270-6.
Score: 0.030
-
Hormone receptor status influences the locoregional benefit of trastuzumab in patients with nonmetastatic breast cancer. Cancer. 2012 Oct 15; 118(20):4936-43.
Score: 0.030
-
Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer. Oncologist. 2011; 16(12):1675-83.
Score: 0.029
-
The impact of age on outcome in early-stage breast cancer. Semin Radiat Oncol. 2011 Jan; 21(1):26-34.
Score: 0.027
-
Patients with only 1 positive hormone receptor have increased locoregional recurrence compared with patients with estrogen receptor-positive progesterone receptor-positive disease in very early stage breast cancer. Cancer. 2011 Apr 15; 117(8):1595-601.
Score: 0.027
-
Estrogen/progesterone receptor negativity and HER2 positivity predict locoregional recurrence in patients with T1a,bN0 breast cancer. Int J Radiat Oncol Biol Phys. 2010 Aug 01; 77(5):1296-302.
Score: 0.026
-
Expression of nuclear transcription factor kappa B in locally advanced human cervical cancer treated with definitive chemoradiation. Int J Radiat Oncol Biol Phys. 2010 Dec 01; 78(5):1331-6.
Score: 0.026
-
Identifying the "sentinel lymph nodes" for arm drainage as a strategy for minimizing the lymphedema risk after breast cancer therapy. Breast Cancer Res Treat. 2009 Aug; 116(3):539-41.
Score: 0.024
-
Radiation use and long-term survival in breast cancer patients with T1, T2 primary tumors and one to three positive axillary lymph nodes. Int J Radiat Oncol Biol Phys. 2008 Jul 15; 71(4):1022-7.
Score: 0.022
-
Comparison of risk of local-regional recurrence after mastectomy or breast conservation therapy for patients treated with neoadjuvant chemotherapy and radiation stratified according to a prognostic index score. Int J Radiat Oncol Biol Phys. 2006 Oct 01; 66(2):352-7.
Score: 0.020
-
Optimizing locoregional control and survival for women with breast cancer: a review of current developments in postmastectomy radiotherapy. Expert Rev Anticancer Ther. 2006 Feb; 6(2):205-16.
Score: 0.020
-
Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin-based neoadjuvant chemotherapy. Cancer. 2005 Aug 15; 104(4):676-81.
Score: 0.019
-
Postmastectomy radiation as a component of the multidisciplinary management of breast cancer patients. Cancer J. 2005 May-Jun; 11(3):198-200.
Score: 0.019
-
Breast conservation after neoadjuvant chemotherapy. Cancer. 2005 Feb 15; 103(4):689-95.
Score: 0.018
-
Inflammatory breast cancer: current concepts in local management. Breast Dis. 2005-2006; 22:75-83.
Score: 0.018
-
Lung carcinoma development after radiotherapy for breast carcinoma. Cancer. 2003 Oct 01; 98(7):1331-3.
Score: 0.017
-
Locoregional treatment outcomes for inoperable anthracycline-resistant breast cancer. Int J Radiat Oncol Biol Phys. 2002 Aug 01; 53(5):1225-33.
Score: 0.015
-
Impact of systemic treatment on local control for patients with lymph node-negative breast cancer treated with breast-conservation therapy. J Clin Oncol. 2001 Apr 15; 19(8):2240-6.
Score: 0.014
-
Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer. JAMA Oncol. 2020 04 01; 6(4):505-511.
Score: 0.013
-
Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype. J Clin Oncol. 2017 Apr 01; 35(10):1049-1060.
Score: 0.010
-
Low expression of galectin-3 is associated with poor survival in node-positive breast cancers and mesenchymal phenotype in breast cancer stem cells. Breast Cancer Res. 2016 09 29; 18(1):97.
Score: 0.010
-
Prognosis for patients with metastatic breast cancer who achieve a no-evidence-of-disease status after systemic or local therapy. Cancer. 2015 Dec 15; 121(24):4324-32.
Score: 0.009
-
Time to treatment as a quality metric in lung cancer: Staging studies, time to treatment, and patient survival. Radiother Oncol. 2015 May; 115(2):257-63.
Score: 0.009
-
International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fifth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2013). J Natl Cancer Inst Monogr. 2015 May; 2015(51):90-6.
Score: 0.009
-
Metastatic Tumor Volume and Extranodal Tumor Extension: Clinical Significance in Patients With Stage II Breast Cancer. Arch Pathol Lab Med. 2015 Oct; 139(10):1288-94.
Score: 0.009
-
Intensity modulated radiotherapy for stage III non-small cell lung cancer in the United States: predictors of use and association with toxicities. Lung Cancer. 2013 Nov; 82(2):252-9.
Score: 0.008
-
(18)F-FDG PET/CT predicts survival in patients with inflammatory breast cancer undergoing neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2013 Dec; 40(12):1809-16.
Score: 0.008
-
Outcomes and predictive factors for salvage therapy after local--regional recurrence following neoadjuvant chemotherapy and breast conserving therapy. Ann Surg Oncol. 2013 Oct; 20(11):3430-7.
Score: 0.008
-
Effect of delay in radiation in the combined modality treatment of breast cancer. Int J Radiat Oncol Biol Phys. 1993 Apr 30; 26(1):23-35.
Score: 0.008
-
Use of radiation therapy in the last 30 days of life among a large population-based cohort of elderly patients in the United States. J Clin Oncol. 2013 Jan 01; 31(1):80-7.
Score: 0.008
-
A population-based study of the quality of care in the diagnosis of large (=5 cm) soft tissue sarcomas. Am J Clin Oncol. 2012 Oct; 35(5):455-61.
Score: 0.008
-
Impact of body mass index on survival outcome among women with early stage triple-negative breast cancer. Clin Breast Cancer. 2012 Oct; 12(5):364-72.
Score: 0.008
-
Multifocality and multicentricity in breast cancer and survival outcomes. Ann Oncol. 2012 Dec; 23(12):3063-3069.
Score: 0.008
-
Impact of internal mammary lymph node drainage identified by preoperative lymphoscintigraphy on outcomes in patients with stage I to III breast cancer. Cancer. 2012 Dec 15; 118(24):6287-96.
Score: 0.008
-
Implications of constructed biologic subtype and its relationship to locoregional recurrence following mastectomy. Breast Cancer Res. 2012 May 23; 14(3):R82.
Score: 0.008
-
Hazard of recurrence among women after primary breast cancer treatment--a 10-year follow-up using data from SEER-Medicare. Cancer Epidemiol Biomarkers Prev. 2012 May; 21(5):800-9.
Score: 0.007
-
Novel staging system for predicting disease-specific survival in patients with breast cancer treated with surgery as the first intervention: time to modify the current American Joint Committee on Cancer staging system. J Clin Oncol. 2011 Dec 10; 29(35):4654-61.
Score: 0.007
-
Occult axillary lymph node metastases do not have prognostic significance in early stage breast cancer. Cancer. 2012 Mar 15; 118(6):1507-14.
Score: 0.007
-
Evaluation of the MD Anderson Prognostic Index for local-regional recurrence after breast conserving therapy in patients receiving neoadjuvant chemotherapy. Ann Surg Oncol. 2012 Mar; 19(3):901-7.
Score: 0.007
-
Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer. J Clin Oncol. 2011 Jul 01; 29(19):2628-34.
Score: 0.007
-
Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy. J Clin Oncol. 2011 May 20; 29(15):1956-62.
Score: 0.007
-
Classification of ipsilateral breast tumor recurrences after breast conservation therapy can predict patient prognosis and facilitate treatment planning. Ann Surg. 2011 Mar; 253(3):572-9.
Score: 0.007
-
Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large population-based study. Cancer. 2011 May 01; 117(9):1819-26.
Score: 0.007
-
Inflammatory breast cancer: the disease, the biology, the treatment. CA Cancer J Clin. 2010 Nov-Dec; 60(6):351-75.
Score: 0.007
-
Prognostic factors of survival in the trastuzumab era among women with breast cancer and brain metastases who receive whole brain radiotherapy: a single-institution review. Cancer. 2010 Jul 01; 116(13):3084-92.
Score: 0.007
-
High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol. 2009 Dec 01; 27(34):5700-6.
Score: 0.006
-
DEAR1 is a dominant regulator of acinar morphogenesis and an independent predictor of local recurrence-free survival in early-onset breast cancer. PLoS Med. 2009 May 26; 6(5):e1000068.
Score: 0.006
-
Prognostic significance of occult axillary lymph node metastases after chemotherapy-induced pathologic complete response of cytologically proven axillary lymph node metastases from breast cancer. Cancer. 2009 Apr 15; 115(8):1605-12.
Score: 0.006
-
Incidence, treatment costs, and complications of lymphedema after breast cancer among women of working age: a 2-year follow-up study. J Clin Oncol. 2009 Apr 20; 27(12):2007-14.
Score: 0.006
-
Staging of breast cancer in the neoadjuvant setting. Cancer Res. 2008 Aug 15; 68(16):6477-81.
Score: 0.006
-
Prognostic significance of HER-2 status in women with inflammatory breast cancer. Cancer. 2008 May 01; 112(9):1905-11.
Score: 0.006
-
Prognostic value of initial clinical disease stage after achieving pathological complete response. Oncologist. 2008 Jan; 13(1):6-15.
Score: 0.006
-
Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy. J Clin Oncol. 2008 Jan 10; 26(2):246-52.
Score: 0.006
-
Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease. Cancer. 2007 Oct 01; 110(7):1436-44.
Score: 0.005
-
Low locoregional failure rates in selected breast cancer patients with tumor-positive sentinel lymph nodes who do not undergo completion axillary dissection. Cancer. 2007 Aug 15; 110(4):723-30.
Score: 0.005
-
Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers. Ann Oncol. 2007 May; 18(5):874-80.
Score: 0.005
-
Role for intraoperative margin assessment in patients undergoing breast-conserving surgery. Ann Surg Oncol. 2007 Apr; 14(4):1458-71.
Score: 0.005
-
Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol. 2006 Mar 01; 24(7):1037-44.
Score: 0.005
-
Squamous cell carcinoma of the breast. J Clin Oncol. 2005 Nov 01; 23(31):7827-35.
Score: 0.005
-
Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy. J Clin Oncol. 2005 Oct 01; 23(28):7098-104.
Score: 0.005
-
Improving local control with breast-conserving therapy: a 27-year single-institution experience. Cancer. 2005 Jul 01; 104(1):20-9.
Score: 0.005
-
Effective local control and long-term survival in patients with T4 locally advanced breast cancer treated with breast conservation therapy. Ann Surg Oncol. 2004 Sep; 11(9):854-60.
Score: 0.004
-
Physician recommendations regarding tamoxifen and patient utilization of tamoxifen after surgery for ductal carcinoma in situ. Cancer. 2004 Mar 01; 100(5):942-9.
Score: 0.004
-
Potential applicability of balloon catheter-based accelerated partial breast irradiation after conservative surgery for breast carcinoma. Cancer. 2004 Feb 01; 100(3):490-8.
Score: 0.004
-
Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma. Cancer. 2004 Feb 01; 100(3):499-506.
Score: 0.004
-
Treatment and outcome of patients with chest wall recurrence after mastectomy and breast reconstruction. Am J Surg. 2004 Feb; 187(2):164-9.
Score: 0.004
-
Chest wall recurrence after mastectomy does not always portend a dismal outcome. Ann Surg Oncol. 2003 Jul; 10(6):628-34.
Score: 0.004
-
Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. Clin Cancer Res. 2003 Jul; 9(7):2406-15.
Score: 0.004
-
Classifying local disease recurrences after breast conservation therapy based on location and histology: new primary tumors have more favorable outcomes than true local disease recurrences. Cancer. 2002 Nov 15; 95(10):2059-67.
Score: 0.004
-
Multidisciplinary management of breast cancer concurrent with pregnancy. J Am Coll Surg. 2002 Jan; 194(1):54-64.
Score: 0.004
-
A case-control study of unilateral and bilateral breast carcinoma patients. Cancer. 2001 May 15; 91(10):1845-53.
Score: 0.004
-
Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: implications for postoperative irradiation. J Clin Oncol. 2000 Aug; 18(15):2817-27.
Score: 0.003
-
Prognostic implications of pathological lymph node status after preoperative chemotherapy for operable T3N0M0 breast cancer. Ann Surg Oncol. 2000 Jul; 7(6):435-40.
Score: 0.003
-
Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer. Am J Surg. 1998 Dec; 176(6):502-9.
Score: 0.003